Supplements and Featured Publications

BEST PRACTICES in Managing FGFRi Treatment–Related AEs: Intrahepatic Cholangiocarcinoma
This article is funded by Taiho Oncology, Inc. The publisher is solely responsible for this content. Taiho does not recommend or endorse the use of its products other than as described in the approved labeling. The content of this article is not medical advice, and does not replace independent medical judgment.
Advertisement
Advertisement
Trending on OncLive
1
Single-Center, Retrospective Data Show Low Rate of Lifileucel Infusion Following Referral in Advanced Melanoma
2
Outcomes With Bridging Therapy Correlate With Cilta-Cel Efficacy, Safety in Multiple Myeloma
3
Real-World Data Support Clinical Benefit With Lifileucel in Previously Treated Advanced Melanoma
4
Long-Term Cilta-Cel Data Show Low Rates of PFS Events in Standard-Risk R/R Myeloma
5

